公开(公告)号：US07902870B1

公开(公告)日：2011-03-08

申请号：US12470943

申请日：2009-05-22

Applicant: Bin Jiang

Inventor： Bin Jiang

IPC: H03L5/00 ,  H03K19/0175

CPC classification number: H03K19/01714 ,  H03K19/018514

Abstract: A level shifter circuit for shifting from a first voltage level technology (such as 0.9 volt) to a second level voltage technology (such as 3.3 volt) with increased switching speed. The increased speed is achieved by adding a boost circuit to the pull-up transistors to boost the switching speed and shut itself down after the transition. The level shifter circuit does not require intermediate level transistors or intermediate level voltage sources.

Abstract translation: 一种用于从第一电压电平技术（例如0.9伏特）转换到具有增加的切换速度的第二电平电压技术（例如3.3伏特）的电平移位器电路。 通过向上拉晶体管添加升压电路以提高开关速度并在转换后关闭自身来实现增加的速度。 电平移位器电路不需要中间级晶体管或中间电平电压源。

公开(公告)号：US07888381B2

公开(公告)日：2011-02-15

申请号：US11451660

申请日：2006-06-13

Applicant: Jingwu Duan ,  Zhonghui Lu ,  David S. Weinstein ,  Bin Jiang

Inventor： Jingwu Duan ,  Zhonghui Lu ,  David S. Weinstein ,  Bin Jiang

IPC: C07D231/56 ,  A01N43/56

CPC classification number: C07D401/04 ,  C07D231/56 ,  C07D401/06 ,  C07D403/04 ,  C07D405/04 ,  C07D405/06 ,  C07D409/06 ,  C07D417/06 ,  C07D417/12

Abstract: Non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) or an enantiomer, a diastereomer, a pharmaceutically acceptable salt, or hydrate thereof, where J is selected from NR1 or C(R4)(R4a); K is selected from NR2 or C(R5)(R5a); L is selected from NR3 or C(R6)(R6a); and A, X, Y, R1, R2, R3, R4, R4a, R5, R5a, R6, R6a, R8, R10, R11, and n are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.

Abstract translation: 提供非甾体化合物，其可用于治疗与调节糖皮质激素受体，AP-1和/或NF-κB活性相关的疾病，包括肥胖症，糖尿病，炎症和免疫疾病，并且具有式 I）或其对映异构体，非对映异构体，药学上可接受的盐或水合物，其中J选自NR 1或C（R 4）（R 4a）; K选自NR2或C（R5）（R5a）; L选自NR 3或C（R 6）（R 6a）; 并且A，X，Y，R 1，R 2，R 3，R 4，R 4a，R 5，R 5a，R 6，R 6a，R 8，R 10，R 11和n如本文所定义。 还提供了治疗肥胖症，糖尿病和包含所述化合物的炎性或免疫相关疾病的药物组合物和方法。

公开(公告)号：US07719314B1

公开(公告)日：2010-05-18

申请号：US12546237

申请日：2009-08-24

Applicant: Bin Jiang ,  Sang Kong Chan

Inventor： Bin Jiang ,  Sang Kong Chan

IPC: H03K19/0175 ,  H03K3/00

CPC classification number: H03K5/01 ,  H03K5/06

Abstract: An interface driver circuit includes a plurality of delay cells. Each delay cell includes a data input, a delayed data output configured to communicate with the data input of an adjacent one of the plurality of delay cells. A delay time input is configured to set a delay value between receiving data at the data input and generating the delayed data output. A plurality of predrivers is configured to receive an output enable signal. A plurality of predrivers is configured to receive a corresponding one of the plurality of delayed data outputs. A plurality of predrivers is configured to generate a predriver output signal based on the output enable signal and the corresponding one of the plurality of delayed data outputs. The output enable signal enables and disables the plurality of predrivers and is independent of data of each delayed data output.

Abstract translation: 接口驱动电路包括多个延迟单元。 每个延迟单元包括数据输入端，被配置为与多个延迟单元中相邻的延迟单元的数据输入通信的延迟数据输出。 延迟时间输入被配置为在数据输入端接收数据和产生延迟的数据输出之间设置延迟值。 多个预驱动器被配置为接收输出使能信号。 多个预驱动器被配置为接收多个延迟数据输出中的对应的一个。 多个预驱动器被配置为基于所述输出使能信号和所述多个延迟数据输出中的相应一个来产生预驱动输出信号。 输出使能信号启用和禁用多个预驱动器，并且独立于每个延迟的数据输出的数据。

公开(公告)号：US20100099328A1

公开(公告)日：2010-04-22

申请号：US12545089

申请日：2009-08-21

Applicant: MAN-ZHONG WANG ,  BIN JIANG ,  SHI-PEI ZHANG

Inventor： MAN-ZHONG WANG ,  BIN JIANG ,  SHI-PEI ZHANG

IPC: A63H3/40

CPC classification number: A63H3/38 ,  A63H3/445

Abstract: A simulated eye is capable of being changeable in an opened state and a closed state. The simulated eye includes an eyeball, an upper eyelid covering the eyeball, a pivot rod, and a driving device having a shaft. The pivot rod is pivotally coupled to the eyeball, the eyelid is fixed to the pivot rod, and the pivot rod is engaged with the shaft and is driven to rotate by the driving device. Accordingly, the upper eyelid is driven to rotate relative to the eyeball by the driving device, so as to simulate an opened state and a closed state of human eyes.

Abstract translation: 模拟眼睛能够在打开状态和关闭状态下变化。 模拟眼睛包括眼球，覆盖眼球的上眼睑，枢轴杆和具有轴的驱动装置。 枢转杆枢转地联接到眼球，眼睑固定到枢轴杆上，枢轴杆与轴接合并被驱动装置驱动旋转。 因此，通过驱动装置驱动上眼睑相对于眼球旋转，以模拟人眼的打开状态和关闭状态。

公开(公告)号：USD603373S1

公开(公告)日：2009-11-03

申请号：US29330563

申请日：2009-01-09

Applicant: Bin Jiang

Designer： Bin Jiang

公开(公告)号：US07554360B1

公开(公告)日：2009-06-30

申请号：US11398387

申请日：2006-04-04

Applicant: Bin Jiang

Inventor： Bin Jiang

IPC: H03K19/0175

CPC classification number: H03K19/01714 ,  H03K19/018514

Abstract: A level shifter circuit for shifting from a first voltage level technology (such as 0.9 volt) to a second level voltage technology (such as 3.3 volt) with increased switching speed. The increased speed is achieved by adding a boost circuit to the pull-up transistors to boost the switching speed and shut itself down after the transition. The level shifter circuit does not require intermediate level transistors or intermediate level voltage sources.

Abstract translation: 一种用于从第一电压电平技术（例如0.9伏特）转换到具有增加的切换速度的第二电平电压技术（例如3.3伏特）的电平移位器电路。 通过向上拉晶体管添加升压电路以提高开关速度并在转换后关闭自身来实现增加的速度。 电平移位器电路不需要中间级晶体管或中间电平电压源。

公开(公告)号：US20090086192A1

公开(公告)日：2009-04-02

申请号：US11863424

申请日：2007-09-28

Applicant: Fan He ,  Shumin Cheng ,  Michael Frenzer ,  Bin Jiang ,  Vahid Goudarzi

Inventor： Fan He ,  Shumin Cheng ,  Michael Frenzer ,  Bin Jiang ,  Vahid Goudarzi

IPC: G01N21/00 ,  G01J3/46 ,  G01N21/25

CPC classification number: G01J1/124 ,  G01J2003/466

Abstract: A system (200) and method (800) for determining whether a sample object (203) has a color that is within a predetermined range is provided. The system (200) includes a light source (201) capable of projecting lights having different light wavelength spectrum upon the sample object (203). A controller (222) causes the light source (201) to project a first light wavelength spectrum upon the sample object (203), then another, then another, and so forth. While each light is projecting upon the object, a monochromatic image capture device (202) captures an image having luminous intensity information. The luminous intensity information, or a subset thereof selected by an image selection tool (232) is then compared to the statistical range, which is derived from a plurality of images taken of a reference object (403).

Abstract translation: 提供了一种用于确定样本对象（203）是否具有在预定范围内的颜色的系统（200）和方法（800）。 系统（200）包括能够将具有不同光波长光谱的光投射到样本物体（203）上的光源（201）。 控制器（222）使得光源（201）将样品（203）上的第一光波长谱投影到另一个，另一个则另一个等等。 当每个光投射在物体上时，单色图像捕获装置（202）捕获具有发光强度信息的图像。 然后将由图像选择工具（232）选择的发光强度信息或其子集与从参考对象（403）拍摄的多个图像导出的统计范围进行比较。

公开(公告)号：US20050182082A1

公开(公告)日：2005-08-18

申请号：US11034822

申请日：2005-01-13

Applicant: Jingwu Duan ,  James Sheppeck ,  Bin Jiang ,  John Gilmore

Inventor： Jingwu Duan ,  James Sheppeck ,  Bin Jiang ,  John Gilmore

IPC: A61K31/439 ,  A61K31/473 ,  A61K31/4748 ,  C07D221/28 ,  C07D401/12 ,  C07D401/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/08

CPC classification number: C07D471/08 ,  C07D401/12 ,  C07D401/14 ,  C07D417/12 ,  C07D417/14

Abstract: A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) its stereoisomers thereof, or a solvate thereof, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, where Z is CONR1R2 or CH2NR1R2 and where at least one of X1-X8 is N, and R, Ra, Rb, Rc and Rd are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.

Abstract translation: 提供了一类新型非甾体化合物，其可用于治疗与糖皮质激素受体，AP-1和/或NF-κB活性的调节相关的疾病，包括肥胖症，糖尿病，炎症和免疫疾病，并且具有 式（I）其立体异构体，或其溶剂化物，或其前药，或其药学上可接受的盐，其中Z为CONR 1，R 2或CH 2 > 2 1 2 其中X 1 -X 8中的至少一个为 N和R，R a，O，R b，R c和R d都在本文中定义。 还提供了治疗肥胖症，糖尿病和包含所述化合物的炎性或免疫相关疾病的药物组合物和方法。